Previous studies by our group showed that Qianliening capsules (QC), a clinically proven effective traditional Chinese formulation that has long been used in the treatment of benign prostatic hyperplasia (BPH), is capable of inhibiting BPH in vivo and in vitro via the promotion
of apoptosis, suppression of the EGFR/STAT3 signaling pathway and regulating the expression of sex hormones as well as their receptors. However, the mechanism of its antiBPH activity has remained to be fully elucidated. The present study aimed to investigate the mechanism underlying the antiproliferative
effect of QC in vivo and in vitro. Castrated male SprageDawley (SD) rats where subcutaneously injected with testosterone propionate and the WPMY1 cell line was stimulated with basic fibroblast growth factor in order to generate BPH in vivo and in vitro separately, both
of which were then subjected to QC treatment. Finasteride was used as a positive control drug for the in vivo study. In the present study, it was found that treatment with QC or finasteride significantly reduced the prostatic index (PI=prostate wet weight/body weight x 100)
in a rat model of BPH (P<0.05). In addition, reverse transcription quantitative polymerase chain reaction (RTPCR) and western blot analyses showed that QC or finasteride treatment significantly inhibited model constructioninduced upregulation of expression of proliferating cell nuclear
antigen, cyclin D1 and cyclin-dependent kinase 4 in prostatic tissues of rats with BPH (P<0.05). The in vitro study further proved that QC exhibited antiproliferative properties via G1/S cell cycle arrest in the WPMY1 cell line, as evidenced by colony formation, flow cytometric
cell cycle, immunoblot and RTPCR analyses. In conclusion, the present study demonstrated that inhibition of cell proliferation via G1/S cell cycle arrest may be one of the underlying mechanisms of the effect of QC on BPH.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China
Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China
Department of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China
Department of Pharmacology, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China
Publication date: August 1, 2015
More about this publication?
Molecular Medicine Reports is a monthly, peer-reviewed journal available in print and online, that includes studies devoted to molecular medicine, underscoring aspects including pharmacology, pathology, genetics, neurosciences, infectious diseases, molecular cardiology and molecular surgery. In vitro and in vivo studies of experimental model systems pertaining to the mechanisms of a variety of diseases offer researchers the necessary tools and knowledge with which to aid the diagnosis and treatment of human diseases.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites